cystamine has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonzi, T | 1 |
| Aiello, A | 1 |
| Petrone, L | 1 |
| Najafi Fard, S | 1 |
| D'Eletto, M | 1 |
| Falasca, L | 1 |
| Nardacci, R | 1 |
| Rossin, F | 1 |
| Delogu, G | 1 |
| Castilletti, C | 1 |
| Capobianchi, MR | 1 |
| Ippolito, G | 1 |
| Piacentini, M | 1 |
| Goletti, D | 1 |
1 other study available for cystamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Topics: Aged; Animals; Antiviral Agents; Cell Line, Tumor; Chlorocebus aethiops; COVID-19; COVID-19 Drug Tre | 2021 |